DXB.ASX: DMX-200 Available To Patients Via Post-Trial Access Pathways

DMX-200 Available To Patients Via Post-Trial Access Pathways

Stock	Dimerix Ltd (DXB.ASX)
Release Time	9 Jul 2026, 8:46 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Dimerix Announces Post-Trial Access for DMX-200

Key Points

DMX-200 available for eligible patients post-trial
Patients who completed ACTION3 trial can continue treatment
Supports ongoing treatment for FSGS patients

Full Summary

Dimerix Limited (ASX: DXB) announced that DMX-200, its investigational treatment for focal segmental glomerular sclerosis (FSGS), will be made available to eligible patients through post-trial access pathways. This initiative allows patients who have completed the ACTION3 Phase 3 trial and Open Label Extension Study to continue receiving DMX-200, subject to consultation with their physician. The post-trial access program reflects Dimerix's commitment to patient continuity of care and the unmet medical need in FSGS patients. Commercial partners will manage access arrangements in their territories, while Dimerix will handle territories without commercial partners. DMX-200 is a chemokine receptor antagonist designed to reduce proteinuria and improve kidney function in FSGS patients.

Outlook

Dimerix remains committed to ensuring that eligible patients have continued access to DMX-200, supporting ongoing treatment for those with FSGS.